Metabolic and immunologic derangements in cardiac cachexia: Where to from here?

Sabine Strassburg, Stefan D. Anker

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

The onset of cardiac cachexia is characterized by a defined severe weight loss in patients with advanced chronic heart failure and it predicts an increased mortality in these patients. Recent studies with potential therapeutics investigated the effects and efficiency of beta-blockers, ghrelin, or ghrelin-agonists in cachexia. These and other new studies, like the influence of heart transplantation on cardiac cachexia, give prospect into potential therapeutic options in the future. General aim of the treatment strategy is to prevent the onset and retard the progress of cachexia. This could be achieved by modifying the metabolic, neurohormonal and immune system abnormalities, e.g. with beta-blockers and angiotensin-converting enzyme inhibitors. However, these alterations interact in a complex pathophysiological process, which is supposed to end in a vicious circle and thereby the wasting process is further promoted. To interrupt this, an early start of therapy is important to decelerate the development of cardiac cachexia. Many further investigations are needed to find out more about the pathophysiological pathways, to confirm the previous results, and to evaluate new therapeutics.

Original languageEnglish
Pages (from-to)57-64
Number of pages8
JournalHeart Failure Reviews
Volume11
Issue number1
DOIs
Publication statusPublished - Mar 2006

Fingerprint

Cachexia
Ghrelin
Therapeutic Uses
Heart Transplantation
Secondary Prevention
Angiotensin-Converting Enzyme Inhibitors
Weight Loss
Immune System
Therapeutics
Heart Failure
Mortality

Keywords

  • Cardiac cachexia
  • Chronic heart failure (CHF)
  • Immune system
  • Metabolism
  • Neurohormones

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Metabolic and immunologic derangements in cardiac cachexia : Where to from here? / Strassburg, Sabine; Anker, Stefan D.

In: Heart Failure Reviews, Vol. 11, No. 1, 03.2006, p. 57-64.

Research output: Contribution to journalArticle

Strassburg, Sabine ; Anker, Stefan D. / Metabolic and immunologic derangements in cardiac cachexia : Where to from here?. In: Heart Failure Reviews. 2006 ; Vol. 11, No. 1. pp. 57-64.
@article{a35f1271c07e4f2aa91f802c2af91d67,
title = "Metabolic and immunologic derangements in cardiac cachexia: Where to from here?",
abstract = "The onset of cardiac cachexia is characterized by a defined severe weight loss in patients with advanced chronic heart failure and it predicts an increased mortality in these patients. Recent studies with potential therapeutics investigated the effects and efficiency of beta-blockers, ghrelin, or ghrelin-agonists in cachexia. These and other new studies, like the influence of heart transplantation on cardiac cachexia, give prospect into potential therapeutic options in the future. General aim of the treatment strategy is to prevent the onset and retard the progress of cachexia. This could be achieved by modifying the metabolic, neurohormonal and immune system abnormalities, e.g. with beta-blockers and angiotensin-converting enzyme inhibitors. However, these alterations interact in a complex pathophysiological process, which is supposed to end in a vicious circle and thereby the wasting process is further promoted. To interrupt this, an early start of therapy is important to decelerate the development of cardiac cachexia. Many further investigations are needed to find out more about the pathophysiological pathways, to confirm the previous results, and to evaluate new therapeutics.",
keywords = "Cardiac cachexia, Chronic heart failure (CHF), Immune system, Metabolism, Neurohormones",
author = "Sabine Strassburg and Anker, {Stefan D.}",
year = "2006",
month = "3",
doi = "10.1007/s10741-006-9193-5",
language = "English",
volume = "11",
pages = "57--64",
journal = "Heart Failure Reviews",
issn = "1382-4147",
publisher = "Springer New York LLC",
number = "1",

}

TY - JOUR

T1 - Metabolic and immunologic derangements in cardiac cachexia

T2 - Where to from here?

AU - Strassburg, Sabine

AU - Anker, Stefan D.

PY - 2006/3

Y1 - 2006/3

N2 - The onset of cardiac cachexia is characterized by a defined severe weight loss in patients with advanced chronic heart failure and it predicts an increased mortality in these patients. Recent studies with potential therapeutics investigated the effects and efficiency of beta-blockers, ghrelin, or ghrelin-agonists in cachexia. These and other new studies, like the influence of heart transplantation on cardiac cachexia, give prospect into potential therapeutic options in the future. General aim of the treatment strategy is to prevent the onset and retard the progress of cachexia. This could be achieved by modifying the metabolic, neurohormonal and immune system abnormalities, e.g. with beta-blockers and angiotensin-converting enzyme inhibitors. However, these alterations interact in a complex pathophysiological process, which is supposed to end in a vicious circle and thereby the wasting process is further promoted. To interrupt this, an early start of therapy is important to decelerate the development of cardiac cachexia. Many further investigations are needed to find out more about the pathophysiological pathways, to confirm the previous results, and to evaluate new therapeutics.

AB - The onset of cardiac cachexia is characterized by a defined severe weight loss in patients with advanced chronic heart failure and it predicts an increased mortality in these patients. Recent studies with potential therapeutics investigated the effects and efficiency of beta-blockers, ghrelin, or ghrelin-agonists in cachexia. These and other new studies, like the influence of heart transplantation on cardiac cachexia, give prospect into potential therapeutic options in the future. General aim of the treatment strategy is to prevent the onset and retard the progress of cachexia. This could be achieved by modifying the metabolic, neurohormonal and immune system abnormalities, e.g. with beta-blockers and angiotensin-converting enzyme inhibitors. However, these alterations interact in a complex pathophysiological process, which is supposed to end in a vicious circle and thereby the wasting process is further promoted. To interrupt this, an early start of therapy is important to decelerate the development of cardiac cachexia. Many further investigations are needed to find out more about the pathophysiological pathways, to confirm the previous results, and to evaluate new therapeutics.

KW - Cardiac cachexia

KW - Chronic heart failure (CHF)

KW - Immune system

KW - Metabolism

KW - Neurohormones

UR - http://www.scopus.com/inward/record.url?scp=33745585099&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745585099&partnerID=8YFLogxK

U2 - 10.1007/s10741-006-9193-5

DO - 10.1007/s10741-006-9193-5

M3 - Article

C2 - 16819578

AN - SCOPUS:33745585099

VL - 11

SP - 57

EP - 64

JO - Heart Failure Reviews

JF - Heart Failure Reviews

SN - 1382-4147

IS - 1

ER -